Shots:
- Vor Bio and RemeGen have entered an exclusive licensing agreement, giving Vor Bio rights outside China, Hong Kong, Macau, and Taiwan to develop & commercialize telitacicept
- As per the Deal, RemeGen will receive $125M ($45M upfront and $80M in stock warrants). RemeGen is eligible for more than $4B in regulatory & commercial milestones + tiered royalties
- Telitacicept is a fusion protein that inhibits BlyS (BAFF) and APRIL, reducing autoreactive B cells and autoantibody production in autoimmune diseases. Approved in China for gMG, SLE, and RA, it is currently in a global P-III trial enrolling in the US, EU, and South America, with initial results expected in the 1H’27
Ref: Globenewswire | Image: Vor Bio & RemeGen| Press Release
Related News:- Daiichi Sankyo and AstraZeneca Report the US FDA Approval of Datroway for Advanced EGFR-Mutated NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
